Enhanced apoptotic effects of novel paclitaxel analogs on NCI/ADR-RES breast cancer cells

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3295-3301

  Yang, Li Xi ^a,c   Zhu, Jun ^a   Wang, Hui Juan ^a   Holton, Robert A ^b  

^a ST MARY S MEDICAL CENTER   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Breast cancer; Multidrug resistance; Paclitaxel; Taxane analogs

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DNA FRAGMENT; PACLITAXEL; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; TL 139; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; NICK END LABELING; PHOSPHORYLATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CASPASES; ENZYME ACTIVATION; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0042530181     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lum BL, Gosland MP, Kaubisch S and Sikic BI: Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109, 1993.
2. Jang SH, Wientjes MG and Au JL: Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 298: 1236-1242, 2001.
3. Botti G, Chiappetta G, D'Aiuto G, de Angelis E, De Matteis A, Montella M, Picone A and Cascione F: PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori 79: 214-228, 1993.
4. Correnti M, Cavazza ME, Guedez N, Herrera O and Suarez-Chacon NR: Expression of the multidrug-resistance (MDR) gene in breast cancer. J Chemother 7: 449-451, 1995.
5. Dahiya R and Deng G: Molecular prognostic markers in breast cancer. Breast Cancer Res Treat 52: 185-200, 1998.
6. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ and Fruehauf JP: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998.
7. Chen G, Teicher BA and Fre E: Differential interactions of P-gp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Anticancer Res 16: 3499-3505, 1996.
8. Plouzek CA, Ciolino H P, Clarke R and Yeh GC: Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer 35: 1541-1545, 1999.
9. Bebawy M, Morris MB and Roufogalis BD: Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer 85: 1998-2003, 2001.
10. Miyata Y, Okada K, Ishibashi S, Asano Y and Muto S: P-gp-induced modulation of regulatory volume increase occurs via PKC in mouse proximal tubule. Am J Physiol Renal Physiol 282: F65-F76, 2002.
11. Lehne G: P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 1: 85-99, 2000.
12. Mooberry SL, Tien G, Hernandez AH, Plubrukarn A and Davidson BS: Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 59: 653-660, 1999.
13. Distefano M, Scambia G, Ferlini C, Gaffini C, Vincenzo RD, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB and Mancuso S: Anti-proliferative activity of a new class of taxanes (14b-hydroxy-10-deacetylabaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 72: 844-850, 1997.
14. Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57: 1215-1221, 1999.
15. Yang LX, Wang HJ and Holton R A: In vitro efficacy of a novel chemoradiopotentiatortaxoltere metro. Int J Radiat Oncol Biol Phys 46: 159-163, 2000.
16. Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC and Borner MM: Uncertain identity of doxorubicin -resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst 92: 1535-1546, 2000.
17. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W and Kalden JR: A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22: 5506-5517, 1994.
18. Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30774, 1994.
19. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, Kamradt JM and Pienta KJ: Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology 54: 746-752, 1999.
20. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK and Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 183: 1957-1964, 1996.
21. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1999.
22. Ogretmen B and Safa AR: Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608-614, 1996.
23. Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628, 2000.
24. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD and Pietenpol J: A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273: 30777-30784, 1998.
25. Srivastava RK, Mi QS, Hardwick JM and Longo DL: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96: 3775-3780, 1999.
26. Haldar S, Basu A and Croce CM: Serine-70 is one of the critical sites for drug induced Bcl-2 phosphorylation in cancer cells. Cancer Res 58: 1609-1615, 1998.
27. Ling YH, Tomos C and Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273: 18984-18991, 1998.
28. Kumar S: Mechanisms mediating caspase activation in cell death. Cell Death Differ 6: 1060-1066, 1999.
29. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
30. Li DW, Xiang H, Mao YW, Wang J, Fass U, Zhang XY and Xu C: Caspase-3 is actively involved in okadaic acid-induced lens epithelial cell apoptosis. Exp Cell Res 266: 279-291, 2001.
31. Puig B, Tortosa A and Ferrer I: Cleaved caspase-3, caspase-7 and poly (ADP-ribose) polymerase are complementarily but differentially expressed in human medulloblastomas. Neurosci Lett 306: 85-88, 2001.
32. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB and Bhalla KN: "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 58: 3202-3208, 1998.